{"disease":{"id":"untreated-advanced-or-recurrent-thymic-carcinomas","name":"untreated advanced or recurrent thymic carcinomas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05832827","title":"First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"National Cancer Center, Japan","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}